How Lipitor Binds to Proteins
Lipitor (atorvastatin), a statin used to lower cholesterol, is highly bound to plasma proteins, primarily albumin, with about 80-90% binding at therapeutic concentrations.[1] This binding limits the free drug available for tissue distribution and metabolism.
Factors That Decrease Protein Binding
- Drug displacement: Co-administration with drugs like gemfibrozil, itraconazole, or cyclosporine competes for albumin sites, reducing atorvastatin binding and increasing free plasma levels, which raises toxicity risk.[1][2]
- Low serum albumin: Conditions such as liver disease, malnutrition, nephrotic syndrome, or critical illness drop albumin levels below 3.5 g/dL, freeing more drug and potentially causing overdose effects.[2]
- High drug concentrations: At supratherapeutic doses (e.g., overdose), binding sites saturate, reducing the percentage bound.[1]
Factors That Increase Protein Binding
- High albumin levels: Elevated albumin from dehydration or other states slightly increases binding, though rarely clinically significant.[2]
- Acidic pH shifts: Lipitor's binding strengthens in more acidic environments (pH ~7.0-7.4), common in blood; alkalosis may weakly reduce it.[3]
Clinical Implications for Patients
Reduced binding elevates free atorvastatin, amplifying myopathy, rhabdomyolysis, or liver enzyme risks—especially in elderly patients or those with renal/hepatic impairment.[1][2] Monitoring involves dose adjustments; avoid high-risk combinations per FDA labeling.[1]
How This Compares to Other Statins
Unlike rosuvastatin (lower 88% binding, less displacement-prone), atorvastatin's higher albumin affinity makes it more sensitive to interactions.[2][4]
[1]: Lipitor Prescribing Information (FDA)
[2]: DrugBank: Atorvastatin
[3]: PubChem: Atorvastatin
[4]: Clinical Pharmacology Review: Statins